S122: MUTANT IDH1 HIJACKS DIFFERENTIATION PROGRAMS IN MYELOID PROGENITOR CELLS TO IMPAIR GRANULOCYTIC DIFFERENTIATION.

• Mariam Hakobyan,
• Jens Langstein,
• Emely Kleinert,
• Maximilian Schönung,
• Mark Hartmann,
• Hannah Rohdjess,
• Sina Staeble,
• Rainer Claus,
• Lars Bullinger,
• Christopher Oakes,
• Karsten Rippe,
• Stefan Fröhling,
• Stefan Pusch,
• Christoph Plass,
• Michael Milsom,
• Daniel B. Lipka

Affiliations

Mariam Hakobyan

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Jens Langstein

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Emely Kleinert

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Maximilian Schönung

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Mark Hartmann

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Hannah Rohdjess

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Sina Staeble

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany

Rainer Claus

3 University of Augsburg, Personalized Tumor Medicine and Molecular Oncology, Faculty of Medicine, Augsburg, Germany

Lars Bullinger

4 Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Tumor Immunology, Berlin, Germany

Christopher Oakes

5 The Ohio State University Comprehensive Cancer Center, Clara D. Bloomfield Center for Leukemia Outcomes Research, Columbus, United States

Karsten Rippe

6 German Cancer Research Center (DKFZ) and Bioquant, Heidelberg, Germany, Division of Chromatin Networks, Heidelberg, Germany

Stefan Fröhling

7 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Division of Translational Medical Oncology, Heidelberg, Germany

Stefan Pusch

8 Heidelberg University Hospital, Department of Neuropathology, Heidelberg, Germany

Christoph Plass

10 German Cancer Research center, Division of Cancer Epigenomics, Heidelberg

Michael Milsom

11 German Cancer Research center, Division of Experimental Hematology, Heidelberg, Germany

Daniel B. Lipka

1 German Cancer Research Center (DKFZ) & National Center for Tumor Diseases (NCT), Section of Translational Cancer Epigenomics, Division of Translational Medical Oncology, Heidelberg, Germany